Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-15T09:49:21.094Z Has data issue: false hasContentIssue false
  • English
  • Français

Continuous Cancer Chemotherapy

Rationale and Prerequisites for Treatment at Home

Published online by Cambridge University Press:  10 March 2009

Peter Schlag
Peter Schlag
Affiliation:
University of Heidelberg
Get access Rights & Permissions [Opens in a new window]

Extract

In the last decade, the incidence of mortality caused by malignant disease has risen. Cancer related deaths are more frequent than those caused by infections or accidents, exceeded only by heart and vascular diseases. In most cases, it is not the primary tumor that kills patients, but its metastatic spread: metastases have a fatal outcome more than 90% of cases (1). By the time metastases have occurred, cure is rarely obtained through surgical procedures. Local radiotherapy to distant metastases is also rarely successful in the treatment of disseminated malignancies. Most patients with metastatic disease need a palliative systemic treatment, which means cytotoxic cancer chemotherapy. Its objective is to destroy cancer cells. Systemic chemotherapy has become standard in the last decades for most disseminated malignancies (1).

Type
Advanced Technology and Health Care in the Home
Information
International Journal of Technology Assessment in Health Care , Volume 1 , Issue 2 , April 1985 , pp. 343 - 351
Copyright
Copyright © Cambridge University Press 1985

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.DeVita, V. T., Hellman, S., & Rosenberg, S. A.Cancer—Principles & practice of oncology. Philadelphia: Lippincott Company, 1982.Google Scholar
2.Ensminger, W. D., & Gyves, J. W.Regional cancer chemotherapy. Cancer Treatment Report, 1984,68, 101–115.Google ScholarPubMed
3.Lokich, J., Bothe, A., Fine, N., & Perri, J.Phase I Study of Protracted Venous Infusion of 5-Fluorouracil. Cancer, 1981, 48, 2565–2568.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
4.Kemeny, N., The systemic chemotherapy of hepatic metastases. Seminars Oncology, 1983, 10, 148–158.Google ScholarPubMed
5.Seifert, P., Baker, L. H., Reed, M. L., & Vaitkevicuis, V. K.Comparison of continuously infused 5-Fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer, 1975, 36, 123–128.3.0.CO;2-C>CrossRefGoogle ScholarPubMed
6.Salem, P., Khalyl, M., Cabboury, K., & Hashimi, L.Cis-dichloroplatinum by 5-Day continuous infusion. Cancer, 1984, 53, 837–840.3.0.CO;2-L>CrossRefGoogle Scholar
7.Lokich, J., & Ensminger, W.Ambulatory pump infusion devices for hepatic arteryinfusion. Seminars Oncology, 1983, 10, 183–190.Google Scholar
8.Perri, J., & Erikson, K. A., Nursing issues for hepatic arterial infusion therapy. Seminars Oncology, 1983, 10, 191–198.Google ScholarPubMed
9.Ballentine, R., Fanning, J., Lawson, M., & Schleper, J.Alternatives in outpatient chemotherapy administration. The Cancer Bulletin, 1980,32, 173–176.Google Scholar
10.Harrison, B. R., & Glenesk, P. T.Continuous infusion 5-Fluorouracil via portable infusion pump. American Journal of Intravenous Therapy and Clinical Nutrition, 1981, 11, 51–62.Google Scholar